Skip to main content
. Author manuscript; available in PMC: 2010 Dec 1.
Published in final edited form as: Trends Pharmacol Sci. 2009 Dec;30(12):638–646. doi: 10.1016/j.tips.2009.09.006

Table 1.

Key residues in HIV-1 Vif that are important for activity against A3G/A3Fa

Vif amino acid Amino acid substitutionsb A3G/A3F affected References
W11 A A3F [92, 93]
Q12 A A3F [93]
14DRMR17 single A substitutions or14AAAA17 A3F [93]
K22 E, D A3G [91, 101, 102]
23SLV25 V25S, AAAc A3F only (V25S) or A3G and A3F [101, 102]
K26 A, D, R A3G [101, 102]
40YRHHY44 single A substitutions or 40AAAAA44, H42N, H43N A3G [93, 124]
E45 G A3G [91]
N48 A A3G [93]
69YxxL72 Y69Ad, L72Ad, L72Sc A3G and A3F [99, 100, 103]
E76 A A3F [99, 100]
W79 A A3F [92, 99, 100]
a

Abbreviations: HIV-1, human immunodeficiency virus type 1; Vif, virion infectivity factor; A3G, APOBEC3G; A3F, APOBEC3F

b

For the amino acids listed, at least one substitution caused Vif activity to be reduced by more than 50% against A3G or A3F, but at least 80% activity was maintained towards the other APOBEC3 protein in infectivity assays.

c

Vif activity against both A3G and A3F was affected in infectivity assays, but the ability to bind A3G/A3F was maintained.

d

Vif activity against both A3G and A3F was affected, but the ability to bind Cullin 5 was maintained.